This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tauber, M. Articles by Rochiccioli, P. Search for Related Content PubMed PubMed Citation Articles by Tauber, M. Articles by Rochiccioli, P.

Growth Hormone (GH) Retesting and Auxological Data in 131 GH-Deficient Patients after Completion of Treatment

Service de Pédiatrie Endocrinologie, Centre, Hospitalier Universitoine, Purpan, F-31059 Toulouse Cedex, France

Address all correspondence and requests for reprints to: Maïthé Tauber, Service de Pédiatrie Endocrinologie, CHU Purpan, Place Baylac, F-31059 Toulouse Cedex, France.

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
GH state and auxological data after completion of GH therapy are reported in 131 patients (79 males, 52 females). They were treated from 1980–1994 for partial (n = 98) or complete (n = 33) GH deficiency (GHD), either idiopathic (n = 121) or organic (n = 10). A single stimulation test (clonidine + betaxolol) was used, and only 50 patients (38%) maintained a blunted response (GH peak below 10 µg/L). Although 9 of the 10 patients with organic GHD had an abnormal low GH peak, 67% of patients with idiopathic GHD normalized their GH secretion. This was particularly true of partial GHD patients (71% vs. 36% of complete GH-deficient patients). Based on a retest GH peak below 5 µg/L, only 23% of the patients were considered to be GH deficient and therefore candidates for GH treatment during adulthood. We found no significant difference between hormonal state at completion of treatment and initial GH deficiency, pubertal state, or sex, although we did find a significantly lower GH peak value before and after treatment in patients with elevated body mass index. Of the 14 obese children who were treated, 50% had an abnormally low serum insulin-like growth factor-I level, arguing for true GHD, and only two children remained obese at cessation of treatment. Auxological data showed that with a mean duration of treatment of 3.6 ± 2.0 yr, patients classified as having complete GHD before treatment had significantly greater catch-up growth as expressed in SDS for height than patients with partial GHD (0.6 ± 1.1 vs. 1.1 ± 0.7 SDS, P < 0.05), and that boys grew better than girls (1.4 ± 0.8 vs. 1.6 ± 0.6 SDS) for height, P < 0.01). That catch-up growth was not correlated with the result of GH peak after cessation of treatment.

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
ALMOST 40 yr since GH was first used in therapy (1), there is still no consensus on what is the best means to study GH secretion and diagnose GH deficiency (GHD) (2, 3, 4, 5). The use of pharmacological or physiological GH tests and the study of spontaneous GH secretion, urinary GH secretion, or indirect data with evaluation of serum insulin-like growth factor-I (IGF-I) and serum IGF-binding protein 3 (IGFBP-3) has been widely discussed. The results of pharmacological and physiological studies of GH secretion appear widely variable on repeated testing (6).

The problem of diagnosing GHD now extends to adulthood, because GHD in adults with childhood or late-onset deficiency has been shown to significantly increase mortality and morbidity (7, 8, 9, 10, 11). In the absence of GH, body mass index (BMI) increased, body composition was modified with an elevated waist/hip ratio, metabolic disorders such as syndrome X were reported, and muscle strength, myocardial efficiency, and bone mineral density were altered. All the abnormal parameters are corrected by GH after either short- or long-term treatment (11, 12, 13, 14, 15).

The incidence and prevalence of adult-onset GHD can be easily evaluated because the majority of cases (about 85%) occur after pituitary surgery. However, the proportion of adults with childhood-onset GHD (those patients who should continue GH treatment after the end of somatic growth) is not known. It thus appears very important to clarify this point. There is little data in the literature on GH state together with auxological data in GHD patients just after completion of GH treatment. For these reasons, we decided to systematically retest patients at the end of GH treatment, and we report here the data of 131 patients treated with GH in our department during the last 14 yr.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
The cohort was composed of 131 patients (79 males and 52 females) who had received GH treatment from 1980–1994 for complete (n = 33) or partial (n = 98) GHD. Treatment was discontinued between 1992 and 1994. Most patients presented with idiopathic GHD (n = 121) and 10 patients presented with organic GHD caused by neurofibromatosis without glioma (n = 1), central nervous system irradiation (n = 2), spina bifida with myelomeningocele (n = 1), medulloblastoma (n = 2), astrocytoma (n = 2), medullar hypoplasia (n = 1), and so-called empty sella turcica (n = 1).

The mean dose of GH was that given in France by France Hypophyse during the last 15 yr and ranged from 0.4–0.6 IU/kg per week.

Table 1 summarizes auxological data: mean chronological age was 16.7 ± 1.7 yr (17.6 ± 1.4 yr for boys and 15.3 ± 1.3 yr for girls), mean bone age 14.8 ± 2.0 yr (15.3 ± 2.0 for boys and 14.2 ± 3.0 for girls), mean BMI was 20 ± 2. Mean duration of treatment was 3.7 ± 2.1 yr, and mean SDS for height increased from -2.7 ± 1.0 SDS before treatment to -1.5 ± 1.0 SDS at the end of treatment.

Before treatment, 33 children (11 girls, 22 boys) were classified as complete GHD because they had two abnormal GH peaks below 5 µg/L after two different stimulation tests. Ninety-eight children (41 girls, 57 boys) were classified as partial GHD because they had either two low GH peaks between 5 and 10 µg/L after stimulation tests (n = 74) or one abnormal test below 10 µg/L and low 24-h GH secretion with an integrated concentration below 2.5 µg/L/min (n = 24). Ten percent of organic GHD patients had partial GHD and 90% had complete GHD. Eighty percent of idiopathic GHD patients had partial GHD and 20% had complete GHD. The ratio between complete and partial GHD did not significantly differ between prepubertal (n = 58) and pubertal (n = 73) patients at the start of treatment. Various stimulation tests were performed either with a single stimulus: ornithine (n = 17), L-dopa (n = 40, clonidine (n = 3), arginine (n = 45), or glucagon (n = 1) or with combined stimuli: clonidine and betaxolol (n = 99), insulin and arginine (n = 13), glucagon and propanolol (n = 10), or glucagon and betaxolol (n = 8). Only a small number of patients were primed with sex steroids before therapy.

During the first year following the discontinuation of therapy and at least 15 days after the last GH injection, each patient came to the day hospital unit for a single GH stimulation test that used clonidine and betaxolol as pharmacological stimuli. This test was the most commonly used test in our department for practical reasons, and most patients had been tested with it before treatment (n = 99).

Hormonal dosages

GH dosage. Kits were purchased from Cis Oris (Cis BioInternational, Gif-sur-Yvette, France) throughout the study. The method changed in 1987 from RIA to immunoradiometric assay. The laboratory compared the values obtained with both methods at this time, and the results were satisfactory. With RIA, the intraassay coefficient of variation (CV) ranged from 7.6–9.2%, and the interassay CV ranged from 11.0–13.7%. With the immunoradiometric assay, the intraassay CV ranged from 2.3–2.8%, and interassay CV ranged from 3.2–4.4%. All the GH dosages at retesting were performed with the same method.

IGF-I dosage. Kits were purchased from the same manufacturer (Mallinckrodt, Medica, Evry, France), and the same method was used for all sera at retesting.

Statistical analysis

We used Pearson’s ² and Yates or Fisher tests for qualitative variables. For quantitative variables, means were compared using covariance analysis to control confounding factors.

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
GH peak at retesting after completion of treatment

Mean value for the group was 14.4 ± 10.0 µg/L (range 0.2–49.5 µg/L). Thirty patients had a blunted response below 5 µg/L (23%), 19 patients had a partially blunted response between 5 and 10 µg/L (15%), and 82 patients had a normal GH peak above 10 µg/L (62%).

Of the 10 patients with organic GHD, only 1 (10%) had a normal GH peak, and 9 still had a low GH peak below 5 µg/L. Conversely, a large majority (67%) of idiopathic GHD patients had a peak above 10 µg/L, 16% had a peak between 5 and 10 µg/L, and 17% had a peak less than 5 µg/L. Data are presented in Fig. 1.

View larger version (44K): [in this window] [in a new window]   Figure 1. Results of GH test in percentages of low, intermediate (between 5 and 10 mg/L), and normal values of GH peak a end of treatment in patients with organic and idiopathic GHD.

View larger version (50K): [in this window] [in a new window]   Figure 2. Results of GH test expressed percentages of low, intermediate (between 5 and 10 mg/L), and normal values of GH peak at end of treatment in patients with complete and partial GHD.

Of the 22 boys with complete GHD, 15 (68%) had a low GH peak and 7 (32%) had a normal test. In the 57 boys with partial GHD, 16 (28%) had a low GH peak and 41 (72%) had a normal test. Therefore 60% of the boys (n = 48) had a normal GH peak, which was not statistically different from the results obtained in girls (64%) and in the group as a whole (62%).

Pubertal stage. Of the 58 children who were prepubertal when starting treatment, 14 (24%) had complete GHD, of whom 10 (72%) still had a low GH peak. In the 44 partial GHD patients, 12 (27%) still had a low GH peak. Therefore 36 (60%) of the 58 children who were prepubertal before treatment had a normal GH test. Of the 73 children who were pubertal at the start of treatment, 19 (26%) had complete GHD, 11 of whom (58%) still had a low GH peak. In the 54 with partial GHD, 16 (30%) still had a low GH peak. Therefore, 63% of the 73 pubertal children had a normal GH test after treatment, which is not statistically different from the result obtained in the group of prepubertal children.

BMI state. When starting treatment, only 14 patients were obese, with a BMI above the 97th percentile, and 8 of those (57%) had complete GHD and 6 (75%) had a low GH peak after completion of treatment. Of the 6 patients with partial GHD, 4 (67%) still had a GH-deficient test. Therefore, at the end of treatment 4/14 (29%) normalized their GH test, which was significantly lower than the result of the whole group (P < 0.001). Only 2/14 remained obese, and these two patients had a GH peak below 5 µg/L. Before treatment, GH peak was also significantly lower (P < 0.001) in the group of obese children than in the nonobese children. Moreover, serum IGF-I levels were obtained in 12 of the 14 patients before treatment and 7 had low values, suggesting that the blunted GH response was not caused by their obesity but related to GHD.

IGF-I plasma levels. We measured IGF-I levels in 119 patients at retesting. The mean value was 358 ± 193 ng/mL and ranged from 37–1149 ng/mL. GH peak at retesting was positively correlated with IGF-I levels (P < 0.02). IGF-I levels were lower in patients with persistent GHD than in those who normalized their GH peak. The difference was more marked in patients with complete GHD (P < 0.001) than in patients with partial GHD (P < 0.004). Conversely, there was no significant difference in IGF-I values between patients with persistent complete GHD and those with partial GHD.

Auxological data

In the 33 patients with complete GHD, mean SDS gain for height was +1.6 ± 1.1 SDS for a mean duration of therapy of 4.3 ± 3.1 yr. We did not find a significant difference in SDS gain between those who normalized their test (n = 12) and those who did not (n = 21) (1.6 ± 0.6 vs. 1.7 ± 1.3 SDS).

In the 98 patients with partial GHD, mean SDS gain for height was 1.1 ± 0.7 SDS for a mean duration of therapy of 3.6 ± 1.7 yr. Again, we did not find a significant difference in SDS gain between those who had a normal test (n = 70) and those who did not (n = 28) (1.1 ± 0.8 vs. 1.2 ± 0.9).

However, patients with complete GHD grew significantly better (P < 0.01) than patients with partial GHD. Boys grew significantly better than girls (P < 0.05): 1.4 ± 0.8 SDS for a duration of 3.8 ± 2.2 yr vs. 1.1 ± 0.7 SDS for a duration of 3.6 ± 2.0 yr. Data are summarized in Table 2.

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

Other criteria of GHD such as plasma IGF-I or IGFBP-3 evaluation could be of interest. It has been documented in adults that serum IGF-I and IGFBP-3 are useful diagnostic tests in identifying young adults with severe GH deficiency if there is a sufficiently large number of age and sex-matched controls (20, 21).

The correlation we found between GH peak and IGF-I levels and the significant difference between the patients who had persistent GHD and those who normalized their test is an argument in favor of transient GHD. Unfortunately, we do not have IGF-I values before treatment or any IGFBP-3 data. Nevertheless, our study helps to predict approximately the number of patients who should continue GH treatment in adulthood. In France, it has been decided that patients should continue treatment if the GH peak is lower than 3 µg/L at retesting. In our series, 23% had complete GHD with a GH peak below 5 µg/L at the end of GH treatment and 14% had a GH peak lower than 3 µg/L. Half of the patients with complete GHD when starting treatment would need to continue GH therapy compared with 14% of partial GHD patients.

This point has been poorly documented in the literature. In one study of 34 patients (22), 19 patients with postirradiation GHD continued to have complete GHD with a GH peak lower than 3.5 µg/L, whereas of 15 idiopathic GH patients, only 26% remained GH deficient. A recent study (23) of 69 adult patients diagnosed as GH deficient in childhood (54 idiopathic GHD, 15 organic), retested by using GHRH + pyridostigmine, found that 57% had persistent GHD with a GH peak below 10 µg/L, of whom 52% had a GH peak below 5 µg/L. In most studies, however, the percentage of patients with complete or partial GHD before treatment is not stated, and this could account for the difference observed. Another study (16) of 50 men (17 with isolated GH deficiency, 33 with multiple pituitary hormone deficiencies) 1.0–15.5 yr after discontinuation of GH therapy for childhood-onset GHD found 100% persistent GHD (GH peak below 7 µg/L) using GHRH or the insulin tolerance test (24).

The auxological data in our study are also interesting, reflecting our strategy of diagnosis and treatment of GHD during the last 14 yr. The sex ratio was 79 boys/52 girls, age at start of treatment was too high, and the mean duration of treatment was significantly different in boys as compared with girls, probably because of the poorer results obtained in the girls. There was no difference in response to GH therapy related to peak GH response after therapy, except for those with GHD before treatment, who grew significantly better than patients with partial GHD.

In conclusion, it is important to retest GHD patients after completion of GH treatment because retesting shows that approximately one-quarter of these patients will need GH treatment in adulthood. This result has to be explained to the families and the patients. It will be of interest to retest all these patients after 1 yr when they return to the department to check their adult height.

	Acknowledgments

 
The authors thank Mlle. Patricia Zanchetta for typing the manuscript, Mme. Nina Crowte for correcting it, and Dr. Charlet for statistical analysis.

Received July 23, 1996.

Revised September 17, 1996.

Revised October 16, 1996.

Accepted October 16, 1996.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 

1. Raben MS. 1958 Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 18:901–903.
2. Rochiccioli P, Enjaume C, Tauber MT, Pienkowski C. 1993 Statistical study of 5743 results of nine pharmacological stimulation tests: a proposed weighting index. Acta Pediatr. 82:245–248.[Medline]
3. Tauber MT, Rochiccioli P. 1996 Exploration of the somatotropic axis. Diabete & Metab. 22:240–244.[Medline]
4. Rochiccioli P, Pienkowski C, Tauber MT, Enjaume C. 1989 Combining pharmacological tests and 24-hour GH secretion (n = 257) for a new classification of GH deficiencies. Horm Res. 31:27–35.
5. Girard J, Fisher-Wasels T. 1990 Measurement of urinary growth hormone. A noninvasive method to assess the growth hormone status. Horm Res. 33:12–18.
6. Cacciari E, Tassoni P, Cicognani A, Pirazzoli P, et al. 1994 Value and limits of pharmacological and physiological tests to diagnose growth hormone (GH) deficiency and predict therapy response: first and second retesting during replacement therapy of patients defined as GH deficient. J Clin Endocrinol Metab. 79:1663–1669.[Abstract]
7. Rosen T, Bengtsson BA. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:285–288.[CrossRef][Medline]
8. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 129:195–200.[Medline]
9. Merola B, Cittadini A, Colao A, et al. 1993 Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab. 77:1658–1661.[Abstract]
10. Merola B, Sofia M, Longobardi S, et al. 1995 Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency. Eur J Endocrinol. 133:680–685.[Abstract/Free Full Text]
11. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. 1993 Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 129:201–206.[Medline]
12. Bengtsson BA, Enden S, Lonn L, et al. 1993 Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 72:309–317.
13. Jorgensen JOL, Pedersen SA, Thuesen L, et al. 1991 Long term growth hormone treatment in growth hormone deficient adults. Acta Endocrinol (Copenh). 125:449–453.[Medline]
14. Salomon F, Cuneo RC, Hesp R, Sonksen PH. 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 321:1797–1803.[Abstract]
15. Jorgensen JOL, Thuesen L, Muller J, Ovesen P, Christiansen JS. 1994 Three years of growth hormone treatment in growth hormone deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol. 130:224–228.[Abstract/Free Full Text]
16. Tassoni P, Carciari E, Cau M, et al. 1990 Variability of growth hormone response to pharmocological and sleep tests performed twice in short children. J Clin Endocrinol Metab. 71:230–234.[Abstract]
17. Rogers RS, Levin RJ, Uriarte M, Barnes KM, Cassorla F, Cutler GB. 1988 The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med. 319:201–207.[Abstract]
18. Donaldson DL, Howell JG, Pan F, Gifford RA, Moore WV. 1989 Growth hormone secretory profiles: variation on consecutive nights. J Pediatr. 115:51–56.[CrossRef][Medline]
19. Zadik Z, Chalew SA, Gilula Z, Kowarski AA. 1990 Reproducibility of growth hormone testing procedures: a comparison between 24-hour integrated concentration and pharmacological stimulation. J Clin Endocrinol Metab. 71:1127–1130.[Abstract]
20. Hoffman DM, O’Sullivan AJ, Baxter RC, Ho KK. 1994 Diagnosis of growth hormone deficiency in adults. Lancet. 343:1064–1068.[CrossRef][Medline]
21. De boer H, Block GJ, Popp-snijders C, Van der veen E. 1994 Diagnosis of growth hormone deficiency in adults. Lancet. 343:1645–1646.[CrossRef][Medline]
22. Clayton PF, Price DA, Shalet SM. 1987 Growth hormone state after completion of treatment with growth hormone. Arch Dis Child. 62:222–226.[Abstract]
23. Longobardi S, Merola B, Pivonello R, et al. 1996 Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab. 81:1244–1247.[Abstract]
24. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. 1996 New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 134:352–356.[Abstract/Free Full Text]

This article has been cited by other articles:

				V Gasco, G Corneli, G Beccuti, F Prodam, S Rovere, J Bellone, S Grottoli, G Aimaretti, and E Ghigo Retesting the childhood-onset GH-deficient patient Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S45 - S52. [Abstract] [Full Text] [PDF]

				G. Corneli, C. Di Somma, F. Prodam, J. Bellone, S. Bellone, V. Gasco, R. Baldelli, S. Rovere, H. J. Schneider, L. Gargantini, et al. Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults Eur. J. Endocrinol., December 1, 2007; 157(6): 701 - 708. [Abstract] [Full Text] [PDF]

				G. Gelwane, C. Garel, D. Chevenne, P. Armoogum, D. Simon, P. Czernichow, and J. Leger Subnormal Serum Insulin-Like Growth Factor-I Levels in Young Adults with Childhood-Onset Nonacquired Growth Hormone (GH) Deficiency Who Recover Normal GH Secretion May Indicate Less Severe but Persistent Pituitary Failure J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3788 - 3795. [Abstract] [Full Text] [PDF]

				N. di Iorgi, A. Secco, F. Napoli, C. Tinelli, A. Calcagno, N. Fratangeli, L. Ambrosini, A. Rossi, R. Lorini, and M. Maghnie Deterioration of Growth Hormone (GH) Response and Anterior Pituitary Function in Young Adults with Childhood-Onset GH Deficiency and Ectopic Posterior Pituitary: A Two-Year Prospective Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3875 - 3884. [Abstract] [Full Text] [PDF]

				S. Zucchini, P. Pirazzoli, F. Baronio, M. Gennari, M. O. Bal, A. Balsamo, S. Gualandi, and A. Cicognani Effect on Adult Height of Pubertal Growth Hormone Retesting and Withdrawal of Therapy in Patients with Previously Diagnosed Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4271 - 4276. [Abstract] [Full Text] [PDF]

				M. Maghnie, L. Ambrosini, M. Cappa, G. Pozzobon, L. Ghizzoni, M. G. Ubertini, N. di Iorgi, C. Tinelli, S. Pilia, G. Chiumello, et al. Adult Height in Patients with Permanent Growth Hormone Deficiency with and without Multiple Pituitary Hormone Deficiencies J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2900 - 2905. [Abstract] [Full Text] [PDF]

				M. E. Molitch, D. R. Clemmons, S. Malozowski, G. R. Merriam, S. M. Shalet, M. L. Vance, and for The Endocrine Society's Clinical Guidelines Su Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1621 - 1634. [Abstract] [Full Text] [PDF]

				M. Maghnie, G. Aimaretti, S. Bellone, G. Bona, J. Bellone, R. Baldelli, C. de Sanctis, L. Gargantini, R. Gastaldi, L. Ghizzoni, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement Eur. J. Endocrinol., April 1, 2005; 152(4): 589 - 596. [Abstract] [Full Text] [PDF]

				J. Leger, S. Danner, D. Simon, C. Garel, and P. Czernichow Do All Patients with Childhood-Onset Growth Hormone Deficiency (GHD) and Ectopic Neurohypophysis Have Persistent GHD in Adulthood? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 650 - 656. [Abstract] [Full Text] [PDF]

				M. Lange, U. Feldt-Rasmussen, O. L. Svendsen, K. W. Kastrup, A. Juul, and J. Muller High Risk of Adrenal Insufficiency in Adults Previously Treated for Idiopathic Childhood Onset Growth Hormone Deficiency J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5784 - 5789. [Abstract] [Full Text] [PDF]

				M. Tauber, B. Jouret, A. Cartault, N. Lounis, M. Gayrard, C. Marcouyeux, C. Pienkowski, I. Oliver, P. Moulin, P. Otal, et al. Adolescents with Partial Growth Hormone (GH) Deficiency Develop Alterations of Body Composition after GH Discontinuation and Require Follow-Up J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5101 - 5106. [Abstract] [Full Text] [PDF]

				M. Tauber, B. Berro, V. Delagnes, N. Lounis, B. Jouret, C. Pienkowski, I. Oliver, and P. Rochiccioli Can Some Growth Hormone (GH)-Deficient Children Benefit from Combined Therapy with Gonadotropin-Releasing Hormone Analogs and GH? Results of a Retrospective Study J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1179 - 1183. [Abstract] [Full Text] [PDF]

				P. Saenger Growth hormone in growth hormone deficiency BMJ, July 13, 2002; 325(7355): 58 - 59. [Full Text] [PDF]

				M. E. Molitch Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 473 - 476. [Full Text] [PDF]

				R. Coutant, S. Rouleau, F. Despert, N. Magontier, D. Loisel, and J.-M. Limal Growth and Adult Height in GH-Treated Children with Nonacquired GH Deficiency and Idiopathic Short Stature: The Influence of Pituitary Magnetic Resonance Imaging Findings J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4649 - 4654. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				J. W. Finkelstein, D. E. Rusovici, E. Green, S. Foreman, H. E. Kulin, M. R. D'Arcangelo, and R. Kemezys Children with Organic Growth Hormone Deficiency Have Elevated Cortisol Responses to Stimuli J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2854 - 2856. [Abstract] [Full Text] [PDF]

				A. S. MartÍnez, H. M. Domené, M. G. Ropelato, H. G. Jasper, P. A. Pennisi, M. E. Escobar, and J. J. Heinrich Estrogen Priming Effect on Growth Hormone (GH) Provocative Test: A Useful Tool for the Diagnosis of GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4168 - 4172. [Abstract] [Full Text]

				G. Aimaretti, C. Baffoni, S. Bellone, L. Di Vito, G. Corneli, E. Arvat, L. Benso, F. Camanni, and E. Ghigo Retesting Young Adults with Childhood-Onset Growth Hormone (GH) Deficiency with GH-Releasing-Hormone-Plus-Arginine Test J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3693 - 3699. [Abstract] [Full Text]

				D. B. Allen Issues in the Transition From Childhood to Adult Growth Hormone Therapy Pediatrics, October 1, 1999; 104(4): 1004 - 1010. [Abstract] [Full Text]

				M. Maghnie, C. Strigazzi, C. Tinelli, M. Autelli, M. Cisternino, S. Loche, and F. Severi Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1324 - 1328. [Abstract] [Full Text]

				G. P. August Symposium on Controversies in the Diagnosis of Growth Hormone Deficiency Pediatrics, August 1, 1998; 102(2): 517 - 517. [Full Text]

				S. M. Shalet, A. Toogood, A. Rahim, and B. M. D. Brennan The Diagnosis of Growth Hormone Deficiency in Children and Adults Endocr. Rev., April 1, 1998; 19(2): 203 - 223. [Abstract] [Full Text]

				R. Coutant, J.-C. Carel, M. Letrait, C. Bouvattier, P. Chatelain, J. Coste, and J.-L. Chaussain Short Stature Associated with Intrauterine Growth Retardation: Final Height of Untreated and Growth Hormone-Treated Children J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1070 - 1074. [Abstract] [Full Text]

				H. de Boer and E. A. van der Veen Why Retest Young Adults with Childhood-Onset Growth Hormone Deficiency? J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2032 - 2036. [Full Text] [PDF]

				R. G. Rosenfeld and M. D. Is Growth Hormone Deficiency a Viable Diagnosis? J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 349 - 351. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tauber, M. Articles by Rochiccioli, P. Search for Related Content PubMed PubMed Citation Articles by Tauber, M. Articles by Rochiccioli, P.